Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

32.33 +1.50 (+4.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Recap: Akero Therapeutics Q3 Earnings
Akero Therapeutics (NASDAQ:AKRO) reported its Q3 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
Via Benzinga
Why Is Akero Therapeutics (AKRO) Stock Up 120% Today?
AKRO stock is soaring 120% and is one of today's top-trending tickers. Akero released positive data on its drug candidate. 
Via InvestorPlace
Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck
Berenberg raised the price target for Merck & Co., Inc. (NYSE: MRK) from $95 to $100. Merck shares rose 0.7% to $86.22 in pre-market trading. 
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
Dow Drops More Than 1,000 Points, Akero Therapeutics Shares Spike Higher
U.S. stocks traded sharply lower toward the end of trading, following the release of inflation data for August. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Akero Therapeutics (NASDAQ: AKRO) Squeezes Shorts After Stronger-then-Expected Results from Phase 2b HARMONY Study of EFX
Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development 
Via Spotlight Growth
Looking Into Akero Therapeutics's Recent Short Interest
Akero Therapeutics's (NASDAQ:AKRO) short percent of float has risen 6.59% since its last report. The company recently reported that it has 6.18 million shares sold short,... 
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
Nasdaq Tumbles 500 Points, Crude Oil Down Over 1%
U.S. stocks extended losses midway through trading, following the release of inflation data for August 
Via Benzinga
Akero Therapeutics Inc. (NASDAQ: AKRO) Sets New 52-Week High in Tuesday Morning Session
Via Investor Brand Network
Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones tumbling more than 800 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Open Lower After Inflation Report, Dow Dips 700 Points
U.S. stocks traded sharply lower this morning, following the release of inflation data for August 
Via Benzinga
What Is Going on With NeuroBo (NRBO) Stock Today?
NeuroBo Pharmaceuticals (NRBO) stock is rocketing higher on Tuesday after the company underwent a reverse stock split this morning. 
Via InvestorPlace
Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment
The company's NASH drug outperformed a placebo at every turn over 24 weeks. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in... 
Via Benzinga
Akero Lead Candidate Improves Fibrosis In Cirrhotic NASH Patients
Akero Therapeutics Inc's (NASDAQ: AKRO) results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis (NASH) have been published in JHEP Reports.  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.